|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.92 SEK | -32.03% |
|
+16,951.28% | +13,658.62% |
| 06-15 | Immunovia Unveils New Data Ahead of Medicare Reimbursement Application | FW |
| 06-15 | Immunovia Announces New Performance Data for PancreaSure Ahead of Upcoming Application for Medicare Coverage | CI |
Company Valuation: Immunovia AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,697 | 595.2 | 92.66 | 152.7 | 117.7 | - | - |
| Change | - | -64.93% | - | 64.79% | -22.91% | - | - |
| Enterprise Value (EV) 1 | 1,443 | 526.7 | 92.66 | 76.09 | 50.72 | 43.72 | 99.72 |
| Change | - | -63.5% | - | -17.88% | -33.35% | -13.8% | 128.1% |
| P/E | -0.11x | -0.04x | -0.01x | -0.54x | -1.75x | -4.38x | -8.75x |
| PBR | 0.04x | 0.02x | - | - | - | - | - |
| PEG | - | -0.01x | - | 0x | 0x | 0.1x | 0.2x |
| Capitalization / Revenue | 1,775x | 494x | - | 203x | 36.8x | 6.8x | 2.14x |
| EV / Revenue | 1,510x | 437x | - | 101x | 15.8x | 2.53x | 1.81x |
| EV / EBITDA | -9.78x | -3.17x | - | -0.97x | -0.57x | -0.55x | -2.12x |
| EV / EBIT | -8.66x | -2.76x | - | -0.95x | -0.56x | -0.53x | -1.99x |
| EV / FCF | -9.27x | -2.97x | - | -0.91x | -0.54x | -0.5x | -1.78x |
| FCF Yield | -10.8% | -33.6% | - | -110% | -185% | -199% | -56.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -689 | -743 | -93 | -0.42 | -0.1 | -0.04 | -0.02 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 0.956 | 1.204 | - | 0.752 | 3.2 | 17.3 | 55 |
| EBITDA 1 | -147.6 | -166.2 | - | -78.06 | -89 | -80 | -47 |
| EBIT 1 | -166.6 | -191.2 | - | -80.38 | -91 | -82 | -50 |
| Net income 1 | -156 | -168.1 | -76.54 | -145.9 | -91 | -82 | -50 |
| Net Debt 1 | -254.1 | -68.47 | - | -76.6 | -67 | -74 | -18 |
| Reference price 2 | 75.0000 | 26.3000 | 0.5460 | 0.2270 | 0.1750 | 0.1750 | 0.1750 |
| Nbr of stocks (in thousands) | 22,632 | 22,632 | 169,711 | 672,667 | 672,667 | - | - |
| Announcement Date | 2/17/22 | 2/23/23 | 2/25/25 | 2/24/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 60.88x | 4.61x | 15.45x | 0.36% | 15.54B | ||
| 38.39x | - | - | 2.11% | 1.65B | ||
| -10.03x | 1.28x | 5.61x | -.--% | 1.09B | ||
| 15.99x | 2.25x | 7.53x | 1.47% | 948M | ||
| 49.42x | - | - | 0.91% | 505M | ||
| 46.97x | - | - | - | 460M | ||
| 17.87x | 2.51x | 10.73x | 1.91% | 365M | ||
| 24.01x | 4.07x | 13.86x | 1.96% | 344M | ||
| Average | 30.44x | 2.94x | 10.64x | 1.24% | 2.61B | |
| Weighted average by Cap. | 51.42x | 4.23x | 14.32x | 0.6% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IMMNOV Stock
- 0G8X Stock
- Valuation Immunovia AB
Select your edition
All financial news and data tailored to specific country editions
















